<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Atrium Therapeutics, Inc. — News on 6ix</title>
<link>https://6ix.com/company/avidity-biosciences-inc</link>
<description>Latest news and press releases for Atrium Therapeutics, Inc. on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Thu, 23 Apr 2026 12:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/avidity-biosciences-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835b94d78dffbe2df11564d.webp</url>
<title>Atrium Therapeutics, Inc.</title>
<link>https://6ix.com/company/avidity-biosciences-inc</link>
</image>
<item>
<title>Atrium Therapeutics Earns $15 Million Milestone Payment from Bristol Myers Squibb Under Global Cardiovascular Collaboration</title>
<link>https://6ix.com/company/avidity-biosciences-inc/news/atrium-therapeutics-earns-dollar15-million-milestone-payment-from-bristol-myers-squibb-under-global-cardiovascular-collaboration-1</link>
<guid isPermaLink="true">https://6ix.com/company/avidity-biosciences-inc/news/atrium-therapeutics-earns-dollar15-million-milestone-payment-from-bristol-myers-squibb-under-global-cardiovascular-collaboration-1</guid>
<pubDate>Thu, 23 Apr 2026 12:00:00 GMT</pubDate>
<description>Atrium Therapeutics, Inc. (Nasdaq: RNA) (the "Company"), a biopharmaceutical company dedicated to delivering RNA therapeutics directly to the heart, announced today it has earned a $15 million development milestone payment from Bristol Myers Squibb (NYSE: BMY). The milestone was achieved upon the successful delivery of a development candidate for the first licensed compound targeting a cardiology indication under the Company's ongoing collaboration.</description>
</item>
<item>
<title>Atrium Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)</title>
<link>https://6ix.com/company/avidity-biosciences-inc/news/atrium-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4</link>
<guid isPermaLink="true">https://6ix.com/company/avidity-biosciences-inc/news/atrium-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4</guid>
<pubDate>Tue, 21 Apr 2026 02:46:00 GMT</pubDate>
<description>Atrium Therapeutics, Inc. (Nasdaq: RNA) (the "Company") today announced it awarded inducement grants on April 20, 2026 under the Company's 2026 Employment Inducement Incentive Award Plan (the "2026 Inducement Plan") as a material inducement to the employment of seven non-executive individuals newly hired by the Company.</description>
</item>
<item>
<title>Atrium Therapeutics Launches with Approximately $270 Million to Advance Novel RNA Medicines for Rare Genetic Cardiomyopathies</title>
<link>https://6ix.com/company/avidity-biosciences-inc/news/atrium-therapeutics-launches-with-approximately-dollar270-million-to-advance-novel-rna-medicines-for-rare-genetic-cardiomyopathies</link>
<guid isPermaLink="true">https://6ix.com/company/avidity-biosciences-inc/news/atrium-therapeutics-launches-with-approximately-dollar270-million-to-advance-novel-rna-medicines-for-rare-genetic-cardiomyopathies</guid>
<pubDate>Fri, 27 Feb 2026 14:19:00 GMT</pubDate>
<description>Atrium Therapeutics, Inc. (Nasdaq: RNA) launched today as a newly independent, publicly traded company dedicated to delivering RNA therapeutics directly to the heart to transform care for people living with rare, life-threatening genetic cardiomyopathies. Atrium Therapeutics was established in connection with Avidity Biosciences, Inc.'s acquisition by Novartis AG. The company is led by Kathleen Gallagher, President and Chief Executive Officer (CEO), and begins operations with two precision cardi</description>
</item>
<item>
<title>Novartis successfully completes acquisition of Avidity Biosciences, strengthening late-stage neuroscience pipeline and advancing xRNA strategy</title>
<link>https://6ix.com/company/avidity-biosciences-inc/news/novartis-successfully-completes-acquisition-of-avidity-biosciences-strengthening-late-stage-neuroscience-pipeline-and-advancing-xrna-strategy-1</link>
<guid isPermaLink="true">https://6ix.com/company/avidity-biosciences-inc/news/novartis-successfully-completes-acquisition-of-avidity-biosciences-strengthening-late-stage-neuroscience-pipeline-and-advancing-xrna-strategy-1</guid>
<pubDate>Fri, 27 Feb 2026 14:00:00 GMT</pubDate>
<description>Adds Avidity’s differentiated muscle-directed Antibody Oligonucleotide Conjugates (AOC) platform and three late-stage programs to industry-leading neuromuscular pipelinePotentially unlocks multi-billion-dollar opportunities with planned product launches before 2030Strengthens late-stage pipeline to further support 2025-2030 net sales CAGR of 5-6% cc and mid to long term growth outlook Basel, February 27, 2026 -- Novartis AG (NYSE: NVS) today announced that it has successfully completed its acqui</description>
</item>
<item>
<title>Avidity Biosciences Announces Multiple Upcoming Presentations at 2026 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference</title>
<link>https://6ix.com/company/avidity-biosciences-inc/news/avidity-biosciences-announces-multiple-upcoming-presentations-at-2026-muscular-dystrophy-association-mda-clinical-and-scientific-conference</link>
<guid isPermaLink="true">https://6ix.com/company/avidity-biosciences-inc/news/avidity-biosciences-announces-multiple-upcoming-presentations-at-2026-muscular-dystrophy-association-mda-clinical-and-scientific-conference</guid>
<pubDate>Thu, 26 Feb 2026 21:02:00 GMT</pubDate>
<description>Avidity Biosciences, Inc. ("Avidity") (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™) to profoundly improve people's lives, today announced that the company will be presenting one oral and six poster presentations at the 2026 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference, being held March 8-11, 2026, in Orlando, Florida.</description>
</item>
<item>
<title>Avidity Biosciences Announces Intention to Adjourn and Reconvene Special Meeting of Stockholders</title>
<link>https://6ix.com/company/avidity-biosciences-inc/news/avidity-biosciences-announces-intention-to-adjourn-and-reconvene-special-meeting-of-stockholders</link>
<guid isPermaLink="true">https://6ix.com/company/avidity-biosciences-inc/news/avidity-biosciences-announces-intention-to-adjourn-and-reconvene-special-meeting-of-stockholders</guid>
<pubDate>Mon, 23 Feb 2026 13:00:00 GMT</pubDate>
<description>Avidity Biosciences, Inc. ("Avidity") (NASDAQ: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates ("AOCs™") to profoundly improve people's lives, today announced that it intends to convene its upcoming special meeting of stockholders (the "Special Meeting") scheduled for February 23, 2026, at 10:00 a.m., Eastern time, and then immediately adjourn proceedings, without conducting any other business. Avidity intends t</description>
</item>
<item>
<title>The New England Journal of Medicine Publishes Results from Phase 1/2 MARINA® Trial of Delpacibart Etedesiran (del-desiran) for Treatment of Myotonic Dystrophy Type 1</title>
<link>https://6ix.com/company/avidity-biosciences-inc/news/the-new-england-journal-of-medicine-publishes-results-from-phase-12-marinar-trial-of-delpacibart-etedesiran-del-desiran-for-treatment-of-myotonic-dystrophy-type-1</link>
<guid isPermaLink="true">https://6ix.com/company/avidity-biosciences-inc/news/the-new-england-journal-of-medicine-publishes-results-from-phase-12-marinar-trial-of-delpacibart-etedesiran-del-desiran-for-treatment-of-myotonic-dystrophy-type-1</guid>
<pubDate>Wed, 18 Feb 2026 22:00:00 GMT</pubDate>
<description>Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that the final results from the completed Phase 1/2 MARINA® trial of delpacibart etedesiran (del-desiran) in people living with myotonic dystrophy type 1 (DM1) will be published in the February 19 issue of The New England Journal of Medicine (NEJM). The manuscript is titled "An Antibody Oligonucleotide Con</description>
</item>
<item>
<title>Avidity Biosciences Announces Expected Record Date for Spin-Off</title>
<link>https://6ix.com/company/avidity-biosciences-inc/news/avidity-biosciences-announces-expected-record-date-spin-2026-02-02</link>
<guid isPermaLink="true">https://6ix.com/company/avidity-biosciences-inc/news/avidity-biosciences-announces-expected-record-date-spin-2026-02-02</guid>
<pubDate>Mon, 02 Feb 2026 05:00:00 GMT</pubDate>
<description>SAN DIEGO, Feb. 2, 2026 /PRNewswire/ -- Avidity Biosciences, Inc. ("Avidity") (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class</description>
</item>
<item>
<title>Avidity Biosciences Announces U.S. Managed Access Program (MAP) for Investigational Therapy del-zota in DMD44</title>
<link>https://6ix.com/company/avidity-biosciences-inc/news/avidity-biosciences-announces-us-managed-access-program-map-investigational-therapy</link>
<guid isPermaLink="true">https://6ix.com/company/avidity-biosciences-inc/news/avidity-biosciences-announces-us-managed-access-program-map-investigational-therapy</guid>
<pubDate>Wed, 19 Nov 2025 05:00:00 GMT</pubDate>
<description>SAN DIEGO, Nov. 19, 2025 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA</description>
</item>
<item>
<title>Avidity Biosciences Reports Third Quarter 2025 Financial Results and Recent Highlights</title>
<link>https://6ix.com/company/avidity-biosciences-inc/news/avidity-biosciences-reports-third-quarter-2025-financial-results-and-recent</link>
<guid isPermaLink="true">https://6ix.com/company/avidity-biosciences-inc/news/avidity-biosciences-reports-third-quarter-2025-financial-results-and-recent</guid>
<pubDate>Mon, 10 Nov 2025 05:00:00 GMT</pubDate>
<description>Announced Novartis agreement to acquire Avidity for total equity value of approximately $12 billion; Avidity expects to separate its early-stage precision</description>
</item>
<item>
<title>Avidity Biosciences Enters into Agreement to be Acquired by Novartis AG</title>
<link>https://6ix.com/company/avidity-biosciences-inc/news/avidity-biosciences-enters-agreement-be-acquired-novartis-ag-2025-10-26</link>
<guid isPermaLink="true">https://6ix.com/company/avidity-biosciences-inc/news/avidity-biosciences-enters-agreement-be-acquired-novartis-ag-2025-10-26</guid>
<pubDate>Sun, 26 Oct 2025 04:00:00 GMT</pubDate>
<description>Novartis to acquire Avidity for USD 72.00 per share in cash for total equity value of approximately USD 12.0 billion Avidity expects to separate its</description>
</item>
<item>
<title>Avidity Biosciences to Participate in Upcoming Investor Conference</title>
<link>https://6ix.com/company/avidity-biosciences-inc/news/avidity-biosciences-participate-upcoming-investor-conference-2025-10-16</link>
<guid isPermaLink="true">https://6ix.com/company/avidity-biosciences-inc/news/avidity-biosciences-participate-upcoming-investor-conference-2025-10-16</guid>
<pubDate>Thu, 16 Oct 2025 04:00:00 GMT</pubDate>
<description>SAN DIEGO, Oct. 16, 2025 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA</description>
</item>
<item>
<title>Avidity Biosciences Announces Positive Pre-BLA Meeting with U.S. FDA for del-zota in DMD44 with a Submission Planned for Q1 2026</title>
<link>https://6ix.com/company/avidity-biosciences-inc/news/avidity-biosciences-announces-positive-pre-bla-meeting-us-fda-del-zota-dmd44</link>
<guid isPermaLink="true">https://6ix.com/company/avidity-biosciences-inc/news/avidity-biosciences-announces-positive-pre-bla-meeting-us-fda-del-zota-dmd44</guid>
<pubDate>Mon, 13 Oct 2025 04:00:00 GMT</pubDate>
<description>SAN DIEGO, Oct. 13, 2025 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA</description>
</item>
<item>
<title>Avidity Biosciences to Present Data from EXPLORE44® Clinical Development Program of Del-Zota in DMD44 at 30th Annual Congress of the World Muscle Society</title>
<link>https://6ix.com/company/avidity-biosciences-inc/news/avidity-biosciences-present-data-explore44r-clinical-development-program-del-zota</link>
<guid isPermaLink="true">https://6ix.com/company/avidity-biosciences-inc/news/avidity-biosciences-present-data-explore44r-clinical-development-program-del-zota</guid>
<pubDate>Mon, 06 Oct 2025 04:00:00 GMT</pubDate>
<description>SAN DIEGO, Oct. 6, 2025 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA</description>
</item>
<item>
<title>Avidity Biosciences, Inc. Announces Closing of Upsized Public Offering of Common Stock, Including Full Exercise of Underwriters' Option to Purchase Additional Shares</title>
<link>https://6ix.com/company/avidity-biosciences-inc/news/avidity-biosciences-inc-announces-closing-upsized-public-offering-common-stock</link>
<guid isPermaLink="true">https://6ix.com/company/avidity-biosciences-inc/news/avidity-biosciences-inc-announces-closing-upsized-public-offering-common-stock</guid>
<pubDate>Mon, 15 Sep 2025 04:00:00 GMT</pubDate>
<description>SAN DIEGO, June 17, 2024 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA</description>
</item>
<item>
<title>Avidity Biosciences Announces Pricing of Upsized Public Offering of Common Stock</title>
<link>https://6ix.com/company/avidity-biosciences-inc/news/avidity-biosciences-announces-pricing-upsized-public-offering-common-stock-2025-09-11</link>
<guid isPermaLink="true">https://6ix.com/company/avidity-biosciences-inc/news/avidity-biosciences-announces-pricing-upsized-public-offering-common-stock-2025-09-11</guid>
<pubDate>Thu, 11 Sep 2025 04:00:00 GMT</pubDate>
<description>SAN DIEGO, Sept. 11, 2025 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA</description>
</item>
<item>
<title>Avidity Biosciences Announces Proposed Public Offering of Common Stock</title>
<link>https://6ix.com/company/avidity-biosciences-inc/news/avidity-biosciences-announces-proposed-public-offering-common-stock-2025-09-10</link>
<guid isPermaLink="true">https://6ix.com/company/avidity-biosciences-inc/news/avidity-biosciences-announces-proposed-public-offering-common-stock-2025-09-10</guid>
<pubDate>Wed, 10 Sep 2025 04:00:00 GMT</pubDate>
<description>SAN DIEGO, Sept. 10, 2025 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA</description>
</item>
<item>
<title>Avidity Biosciences' Del-zota Demonstrated Reversal of Disease Progression Across Key Functional Endpoints in EXPLORE44® and EXPLORE44-OLE™ Phase 1/2 Trial in People Living with DMD44</title>
<link>https://6ix.com/company/avidity-biosciences-inc/news/avidity-biosciences-del-zota-demonstrated-reversal-disease-progression-across-key</link>
<guid isPermaLink="true">https://6ix.com/company/avidity-biosciences-inc/news/avidity-biosciences-del-zota-demonstrated-reversal-disease-progression-across-key</guid>
<pubDate>Wed, 10 Sep 2025 04:00:00 GMT</pubDate>
<description>-- Unprecedented improvement compared to baseline and natural history in multiple functional measures including Time to Rise from Floor (TTR), 4-Stair Climb</description>
</item>
<item>
<title>Avidity Biosciences to Participate in Upcoming Investor Conferences</title>
<link>https://6ix.com/company/avidity-biosciences-inc/news/avidity-biosciences-participate-upcoming-investor-conferences-2025-08-27</link>
<guid isPermaLink="true">https://6ix.com/company/avidity-biosciences-inc/news/avidity-biosciences-participate-upcoming-investor-conferences-2025-08-27</guid>
<pubDate>Wed, 27 Aug 2025 04:00:00 GMT</pubDate>
<description>SAN DIEGO, Aug. 27, 2025 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA</description>
</item>
<item>
<title>Avidity Biosciences Reports Second Quarter 2025 Financial Results and Recent Highlights</title>
<link>https://6ix.com/company/avidity-biosciences-inc/news/avidity-biosciences-reports-second-quarter-2025-financial-results-and-recent</link>
<guid isPermaLink="true">https://6ix.com/company/avidity-biosciences-inc/news/avidity-biosciences-reports-second-quarter-2025-financial-results-and-recent</guid>
<pubDate>Thu, 07 Aug 2025 04:00:00 GMT</pubDate>
<description>Aligned with FDA on del-brax accelerated and full approval pathways for FSHD, reported positive topline data from Phase 1/2 FORTITUDE™ trial, and initiated</description>
</item>
</channel>
</rss>